Journal ArticleDOI
TFOS DEWS II Epidemiology Report.
Fiona Stapleton,Monica Alves,Vatinee Y Bunya,Isabelle Jalbert,Kaevalin Lekhanont,Florence Malet,Kyung Sun Na,Debra A. Schaumberg,Miki Uchino,Jelle Vehof,Eloy Viso,Susan Vitale,Lyndon Jones +12 more
Reads0
Chats0
TLDR
The subcommittee reviewed the prevalence, incidence, risk factors, natural history, morbidity and questionnaires reported in epidemiological studies of dry eye disease and confirmed that prevalence increases with age, however signs showed a greater increase per decade than symptoms.Abstract:
The subcommittee reviewed the prevalence, incidence, risk factors, natural history, morbidity and questionnaires reported in epidemiological studies of dry eye disease (DED). A meta-analysis of published prevalence data estimated the impact of age and sex. Global mapping of prevalence was undertaken. The prevalence of DED ranged from 5 to 50%. The prevalence of signs was higher and more variable than symptoms. There were limited prevalence studies in youth and in populations south of the equator. The meta-analysis confirmed that prevalence increases with age, however signs showed a greater increase per decade than symptoms. Women have a higher prevalence of DED than men, although differences become significant only with age. Risk factors were categorized as modifiable/non-modifiable, and as consistent, probable or inconclusive. Asian ethnicity was a mostly consistent risk factor. The economic burden and impact of DED on vision, quality of life, work productivity, psychological and physical impact of pain, are considerable, particularly costs due to reduced work productivity. Questionnaires used to evaluate DED vary in their utility. Future research should establish the prevalence of disease of varying severity, the incidence in different populations and potential risk factors such as youth and digital device usage. Geospatial mapping might elucidate the impact of climate, environment and socioeconomic factors. Given the limited study of the natural history of treated and untreated DED, this remains an important area for future research.read more
Citations
More filters
Journal ArticleDOI
TFOS DEWS II Definition and Classification Report
Jennifer P. Craig,Kelly K. Nichols,Esen K. Akpek,Barbara Caffery,Harminder S Dua,Choun Ki Joo,Zuguo Liu,J. Daniel Nelson,J. Daniel Nelson,Jason J. Nichols,Kazuo Tsubota,Fiona Stapleton +11 more
TL;DR: The new definition recognizes the multifactorial nature of dry eye as a disease where loss of homeostasis of the tear film is the central pathophysiological concept and central to the scheme is a positive diagnosis of DED with signs and symptoms, and this is directed towards management to restore homeostosis.
Journal ArticleDOI
TFOS DEWS II Diagnostic Methodology report
James S. Wolffsohn,Reiko Arita,Robin L. Chalmers,Ali R. Djalilian,Murat Dogru,Kathy Dumbleton,Preeya K. Gupta,Paul M. Karpecki,Sihem Lazreg,Heiko Pult,Benjamin Sullivan,Alan Tomlinson,Louis Tong,Edoardo Villani,Kyung Chul Yoon,Lyndon Jones,Jennifer P. Craig +16 more
TL;DR: The role of the Tear Film and Ocular Surface Society (TFOS) Dry Eye Workshop (DEWS) II Diagnostic Methodology Subcommittee was to identify tests used to diagnose and monitor dry eye disease (DED) to identify those most appropriate to fulfil the definition of DED and its sub-classifications.
Journal ArticleDOI
TFOS DEWS II pathophysiology report
Anthony J. Bron,Anthony J. Bron,Cintia S. de Paiva,Sunil K. Chauhan,Stefano Bonini,Eric E. Gabison,Sandeep Jain,Erich Knop,Maria Markoulli,Yoko Ogawa,Victor L. Perez,Yuichi Uchino,Norihiko Yokoi,Driss Zoukhri,David A. Sullivan +14 more
TL;DR: The TFOS DEWS II Pathophysiology Subcommittee reviewed the mechanisms involved in the initiation and perpetuation of dry eye disease, finding the targeting of the terminal duct in meibomian gland disease and the influence of gaze dynamics and the closed eye state on tear stability and ocular surface inflammation to be important.
Journal ArticleDOI
TFOS DEWS II Management and Therapy Report
Lyndon Jones,Laura E Downie,Donald R. Korb,Jose M. Benitez-del-Castillo,Reza Dana,Sophie X. Deng,Pham N. Dong,Gerd Geerling,Richard Y Hida,Yang Liu,Kyoung Yul Seo,Joseph Tauber,Tais Hitomi Wakamatsu,Jianjiang Xu,James S. Wolffsohn,Jennifer P. Craig +15 more
TL;DR: It became clear that many of the treatments available for the management of dry eye disease lack the necessary Level 1 evidence to support their recommendation, often due to a lack of appropriate masking, randomization or controls and in some cases due to issues with selection bias or inadequate sample size.
Journal ArticleDOI
TFOS DEWS II Report Executive Summary
Jennifer P. Craig,J. Daniel Nelson,J. Daniel Nelson,Dimitri T. Azar,Carlos Belmonte,Anthony J. Bron,Anthony J. Bron,Sunil K. Chauhan,Cintia S. de Paiva,José Álvaro Pereira Gomes,Katherine M. Hammitt,Lyndon Jones,Jason J. Nichols,Kelly K. Nichols,Gary D. Novack,Gary D. Novack,Fiona Stapleton,Mark D. P. Willcox,James S. Wolffsohn,David A. Sullivan +19 more
TL;DR: This article presents an Executive Summary of the conclusions and recommendations of the 10-chapter TFOS DEWS II report.
References
More filters
Journal ArticleDOI
The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.
John E. Ware,Cathy D. Sherbourne +1 more
TL;DR: A 36-item short-form survey designed for use in clinical practice and research, health policy evaluations, and general population surveys to survey health status in the Medical Outcomes Study is constructed.
Journal ArticleDOI
Meta-Analysis in Clinical Trials*
TL;DR: This paper examines eight published reviews each reporting results from several related trials in order to evaluate the efficacy of a certain treatment for a specified medical condition and suggests a simple noniterative procedure for characterizing the distribution of treatment effects in a series of studies.
The mos 36- item short form health survey (sf- 36) conceptual framework and item selection
Ware J.E.Jr.,C D Sherburne +1 more
Journal ArticleDOI
Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II.
Reva C. Lawrence,David T. Felson,Charles G. Helmick,Lesley M. Arnold,Hyon K. Choi,Richard A. Deyo,Sherine E. Gabriel,Rosemarie Hirsch,Marc C. Hochberg,Gene G. Hunder,Joanne M. Jordan,Jeffrey N. Katz,Hilal Maradit Kremers,Frederick Wolfe +13 more
TL;DR: This report provides the best available prevalence estimates for the US for osteoarthritis, polymyalgia rheumatica, gout, fibromyalgia, and carpal tunnel syndrome as well as the symptoms of neck and back pain.
National Arthritis Data Work-group. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II
Reva C. Lawrence,David T. Felson,Charles G. Helmick,LM Arnold,Hyon K. Choi,Richard A. Deyo,LM Helmick Cg Arnold,Sherine E. Gabriel,Rosemarie Hirsch,Marc C. Hochberg,Gene G. Hunder,Joanne M. Jordan,Jeffrey N. Katz,Hilal Maradit Kremers,Frederick Wolfe,FC Arnett +15 more
TL;DR: In this paper, the best available estimates of the US prevalence of and number of individuals affected by osteoarthritis, polymyalgia rheumatica and giant cell arteritis, gout, fibromyalgia, and carpal tunnel syndrome, as well as the symptoms of neck and back pain are provided.